Vivelle-Dot Side Effects
Generic name: estradiol
Note: This document contains side effect information about estradiol. Some of the dosage forms listed on this page may not apply to the brand name Vivelle-Dot.
Some side effects of Vivelle-Dot may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to estradiol: oral tablet
Other dosage forms:
Get emergency medical help if you have any of these signs of an allergic reaction while taking estradiol (the active ingredient contained in Vivelle-Dot) hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using estradiol and call your doctor at once if you have a serious side effect such as:
unusual vaginal bleeding (especially if you are past menopause);
chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden severe headache, confusion, problems with vision, speech, or balance;
stabbing chest pain, sudden cough, wheezing, rapid breathing, fast heart rate;
pain, swelling, warmth, or redness in one or both legs;
nausea, vomiting, loss of appetite, increased thirst, muscle weakness, confusion, and feeling tired or restless;
a lump in your breast;
feeling like you might pass out;
pain, swelling, or tenderness in your stomach; or
jaundice (yellowing of the skin or eyes).
Less serious side effects of estradiol may include:
mild nausea, vomiting, bloating, stomach cramps;
breast pain, tenderness, or swelling;
freckles or darkening of facial skin;
loss of scalp hair;
vaginal itching or discharge; or
changes in your menstrual periods, break-through bleeding.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to estradiol: compounding powder, intramuscular solution, oral tablet, transdermal emulsion, transdermal film extended release, transdermal gel, transdermal spray, vaginal ring
Cases of oral pigmentation and ischemic colitis have been reported rarely.
Gastrointestinal side effects have included nausea, abdominal cramps, bloating and vomiting. Some studies have demonstrated a 2 to 4 fold increase in gallbladder disease in postmenopausal women taking estrogen therapy. Cholestatic jaundice, pancreatitis, and enlargement of hepatic hemangiomas have been reported. Post marketing experience with the vaginal ring has included a few cases of bowel obstruction and vaginal ring use.
Oncologic side effects have included reports of an increased risk of endometrial carcinoma in patients with an intact uterus and less persuasively, with an increased risk of breast cancer.
A number of studies have suggested that the risk of endometrial carcinoma is removed (or delayed) by the administration of progestins in combination with estrogen therapy.
The increased risk of breast cancer due to use of estrogens is controversial. Several studies have suggested that long-term estrogen therapy may be associated with a slightly increased risk of breast cancer. Meta analysis of 51 studies (epidemiological data) supports a modest risk increase associated with long-term hormone replacement therapy (HRT).
One study of Swedish women has reported that a 10% increase in the relative risk of breast cancer may occur and that the risk is related to increasing duration of estrogen therapy. In that study, women with more than nine years of estrogen use had a 70% greater relative risk of breast cancer than controls. That study, however, examined use of a variety of estrogen preparations of which estradiol was the most frequently prescribed. In addition, women who took progestins did not demonstrate a decreased risk of breast cancer and may even have been at higher risk.
The Toronto Breast Cancer Study has reported that women who receive unopposed conjugated estrogens for less than 15 years are not at increased risk of breast cancer. In that study, an increase in the risk of breast cancer for women who used conjugated estrogens for more than 15 years was not ruled out.
The Case-Control Surveillance Study has reported that there is "no evidence that the use of unopposed conjugated estrogens increases the risk of breast cancer, even after long duration of use or long latent intervals, but the possibility of a modest increase (less than a doubling) could not be excluded."
Follow-up to the Nurses' Health Study of 1992 concluded, however, that there is an increased risk of breast cancer in women taking estrogen replacement therapy and that the risk is not reduced by concurrent use of progestins. (In that study, greater risk was associated with advanced age and prolonged duration of hormonal therapy.)
A study of middle-aged women in the Puget Sound area concluded that "on the whole, the use of estrogen with progestin HRT [hormone replacement therapy] does not appear to be associated with an increased risk of breast cancer in middle-aged women."
A prospective cohort study (11 years) of 37,105 women by Gapstur et al evaluated the histology of the breast cancer in women who ever used HRT. No association was found between duration of ever HRT use and the incidence of ductal carcinoma in situ or invasive ductal/lobular carcinoma. The duration of ever HRT use was associated with risk of invasive carcinoma with a favorable prognosis (relative risk (RR) = 1.81, 95% confidence interval (CI), 1.07 to 3.07 for HRT use less than or equal to 5 yrs and RR = 2.65, CI, 1.32 to 5.23 for HRT use > 5 yrs, p = 0.005). The relative risk of invasive carcinoma with a favorable prognosis for current users (adjusted for age and other risk factors) was 4.42, CI, 2.00 to 9.76 for less than or equal to 5 yrs and 2.63, CI, 1.18 to 5.89 for > 5 yrs). Risk of invasive ductal or lobular carcinoma for current users less than or equal to 5 yrs was RR = 1.38, CI, 1.03 to 1.85.
The reported effects of estrogens on cardiovascular activity are variable. Alterations in lipid profiles in treated women are thought to be responsible for reducing cardiovascular risks. Data suggest estrogen use may increase blood pressure, particularly in patients receiving high doses, decrease blood pressure, or result in no change. In addition, noncontraceptive use of estrogens in young women (particularly smokers) may substantially increase the risk of nonfatal myocardial infarction. Other studies have concluded that no increased risk of myocardial infarction exists.
Cardiovascular side effects have included studies suggesting that unopposed estrogen therapy decreased the risk of coronary heart disease by as much as 35%. Combination therapy with a progestin may have also decreased coronary risk. However, the extent of risk reduction with combination therapy has not been determined. Data are available that suggest combination therapy does not reduce the overall rate of coronary heart disease in postmenopausal women with established coronary disease.
Metabolic side effects have included reports of generally favorable alterations in plasma lipid profiles. Specifically, increased HDL and decreased cholesterol and LDL levels have occurred. Estrogen therapy may have led to increased serum triglyceride levels resulting in pancreatitis in patients with familial lipoprotein metabolic defects.
Metabolic adverse effects such as hypercalcemia have occurred in patients with breast cancer and bone metastases.
Endocrine side effects have included increased levels of thyroxin-binding globulin which led to increased total thyroid serum levels and a decreased in resin uptake of T3. Free thyroid hormone levels remained unchanged. Other endocrine effects have included decreased fasting plasma glucose.
General side effects have included fluid retention and mastodynia. Alterations in libido have occurred. Post marketing experience with the vaginal ring has included a few cases of toxic shock syndrome.
Many of the reports of hepatic tumors have occurred in women taking long-term oral contraceptives. However, some tumors have been reported in women taking isolated estrogen therapy.
Hepatic side effects have included reports of focal nodular hyperplasia, liver cell adenomas, hepatic hemangiomas, and well-differentiated hepatocellular carcinomas. Aggravation of porphyria has been reported.
Hematologic side effects have included hypercoagulability and an increase in venous thromboembolism.
The clinical significance of such hypercoagulability in postmenopausal women taking estrogens has not been determined.
Ocular side effects have included alterations in corneal curvature and contact lens discomfort. Retinal vascular thrombosis has been reported.
Hypersensitivity side effects have included reports of reactions including anaphylaxis. Some reports have implicated the dyes contained in some conjugated estrogen formulations. Urticaria and angioedema have also been reported.
Postmarketing reports concerning a transdermal product (Climara) have included a few cases in which there were a combination of the symptoms of generalized hives or rash with swelling of the throat or eyelid edema.
Other side effects have included reports of a possible increase in the risk of "fibrocystic breast disease" by as much as twofold.
Psychiatric side effects have included case reports of rapid mood cycling in patients with severe depression.
Nervous system side effects have included dementia, dizziness, mental depression, headache, nervousness, irritability exacerbation of epilepsy and new onset or exacerbation of migraine headaches. A case of chorea has been reported in association with estrogen therapy.
Dermatologic side effects have included chloasma or melasma, which did not always resolve following discontinuation of estrogen therapy. Scalp hair loss, hirsutism, erythema nodosum, and hemorrhagic eruptions have occurred.
Genitourinary side effects have included abnormal uterine bleeding and dysmenorrhea. In some cases, this was bleeding related to endometrial carcinoma. In addition, estrogens have increased the size of preexisting uterine leiomyomata. Post marketing experience with the vaginal ring has included a few cases of ring adherence to the vaginal wall, making removal difficult.
Musculoskeletal side effects have included arthralgias.
More Vivelle-Dot resources
- Vivelle-Dot Prescribing Information (FDA)
- Vivelle-Dot Advanced Consumer (Micromedex) - Includes Dosage Information
- Estradiol Professional Patient Advice (Wolters Kluwer)
- estradiol MedFacts Consumer Leaflet (Wolters Kluwer)
- Estradiol Prescribing Information (FDA)
- Estradiol Monograph (AHFS DI)
- estradiol Transdermal Advanced Consumer (Micromedex) - Includes Dosage Information
- Alora Prescribing Information (FDA)
- Climara Prescribing Information (FDA)
- Climara Consumer Overview
- Climara weekly patch MedFacts Consumer Leaflet (Wolters Kluwer)
- Delestrogen Prescribing Information (FDA)
- Delestrogen MedFacts Consumer Leaflet (Wolters Kluwer)
- Depo-Estradiol MedFacts Consumer Leaflet (Wolters Kluwer)
- Depo-Estradiol Prescribing Information (FDA)
- Estrace Advanced Consumer (Micromedex) - Includes Dosage Information
- Estrace MedFacts Consumer Leaflet (Wolters Kluwer)
- Estrace Consumer Overview
- Estrace Prescribing Information (FDA)
- Estraderm patch MedFacts Consumer Leaflet (Wolters Kluwer)
- Estraderm Prescribing Information (FDA)
- Estradiol Patch Prescribing Information (FDA)
- Estrasorb emulsion MedFacts Consumer Leaflet (Wolters Kluwer)
- Estrasorb Consumer Overview
- Estrasorb Prescribing Information (FDA)
- Evamist spray MedFacts Consumer Leaflet (Wolters Kluwer)
- Evamist Consumer Overview
- Evamist Prescribing Information (FDA)
- Femring Prescribing Information (FDA)
- Femring ring MedFacts Consumer Leaflet (Wolters Kluwer)
- Femtrace Prescribing Information (FDA)
- Femtrace Advanced Consumer (Micromedex) - Includes Dosage Information
- Femtrace Consumer Overview
- Femtrace MedFacts Consumer Leaflet (Wolters Kluwer)
- Menostar weekly patch MedFacts Consumer Leaflet (Wolters Kluwer)
- Menostar Prescribing Information (FDA)
- Menostar Consumer Overview
- Minivelle Prescribing Information (FDA)
- Vivelle Prescribing Information (FDA)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.